$FATE on NASDAQ
March 05, 2024
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
Fate Therapeutics to Present at Upcoming March Investor Conferences
February 26, 2024
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 15, 2024
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
February 02, 2024
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2024
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
December 13, 2023
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2023
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
October 25, 2023
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
August 31, 2023
Fate Therapeutics to Present at Upcoming September Investor Conferences
August 08, 2023
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
July 28, 2023
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
May 31, 2023
Fate Therapeutics to Present at Upcoming June Investor Conferences
May 03, 2023
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
April 24, 2023
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
March 03, 2023
Fate Therapeutics to Present at Upcoming March Investor Conferences
February 28, 2023
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 13, 2023
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
January 05, 2023
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
December 13, 2022
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
December 10, 2022
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
December 10, 2022
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
November 07, 2022
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
November 04, 2022
Fate Therapeutics to Present at Upcoming Investor Conferences
November 03, 2022
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
November 03, 2022
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
October 24, 2022
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
October 05, 2022
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting
September 02, 2022
Fate Therapeutics to Participate at Upcoming September Investor Conferences
August 09, 2022
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells
August 03, 2022
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
July 25, 2022
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
June 30, 2022
Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer
June 28, 2022
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies
June 03, 2022
Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
May 06, 2022
Fate Therapeutics to Present at Upcoming May Investor Conferences
May 04, 2022
Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress
April 22, 2022
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results
March 02, 2022
Fate Therapeutics to Present at Upcoming March Investor Conferences
February 28, 2022
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress
February 16, 2022
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results
February 02, 2022
Fate Therapeutics to Present at Upcoming February Investor Conferences
January 10, 2022
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
December 13, 2021
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
December 13, 2021
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
December 08, 2021
Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting
November 11, 2021
Fate Therapeutics to Present at Upcoming Investor Conferences
November 09, 2021
Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference
November 04, 2021
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
November 04, 2021
Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting
- No Recent Filings Found.
